DT-01 · Dosing / Timing Recommendation
Dosing / timing recommendationSynthetic demo dataTarget state: Nausea · onset 5 d · prior: symptom −16%, persistence +8%, tolerance +11%Simulate for P-02005
For P-02005
Eligible at 54% confidence. Among the 284 most similar trajectories: 11 accepted, 91% improved, mean effect −20%.
What it is
A dosing / timing recommendation to the investigator: shift the dose relative to meals or time of day (e.g. evening dosing, dose 30 min after a meal), with a 7-day observation window in the companion.
How it works
Changes drug exposure kinetics and the overlap between peak exposure and the gut's most sensitive window. Highest yield in exposure-led toxicity.
What the patient does, day by day
| Day 0 | 🏥 | Investigator authorization Required; LIFE OS never changes dosing on its own. |
| Every day | ✓ | Take the dose after a meal / in the evening Companion reminder at the new time. |
| Every day | ✓ | GI and toxicity check-in Observation window for the rechallenge. |
Delivery
- Owner
- Investigator
- Channel
- Investigator authorizes; companion enforces the new timing
- Duration
- 7 days
- Touchpoints
- Timing reminder daily
- Cost
- ≈ €60 per patient
Monitoring
- · GI
- · Toxicity labs at day 7
- · Sleep (evening dosing)
Stop rules
- · Toxicity rises within 7 days → revert
Contraindications
- · Poor metabolizers without investigator authorization
- · Assets with strict fasting requirements
Evidence in META-24
19 accepted · 84% improved · mean effect −18%By biology segment
| Low butyrate capacity | n 13 | 92% |
| Low microbial diversity | n 13 | 92% |
| IL6 high-expression variant | n 6 | 83% |
| FUT2 non-secretor | n 5 | 60% |
By trajectory cluster
| ET | n 16 | 94% |
Works best when
- · Toxicity peaks on dosing days
- · Exposure-led theory leading
Works poorly when
- · Diet-led or behaviour-led patterns
What the model has learned about it
No learned rule yet for DT-01. Run learning after campaign results.
Campaigns using it
None yet. 158 patients look eligible right now.